ReviewFrontiers in cellular and infection microbiology2020
Gut Microbiota Approach-A New Strategy to Treat Parkinson's Disease.
Review in Frontiers in cellular and infection microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Targeting TREM2 for Parkinson's Disease: Where to Go?Frontiers in immunology · 2021Pooled it
- Preventive Attenuation of MPTP-Induced Parkinson's Disease-like Abnormalities byFoods (Basel, Switzerland) · 2026Article
- The relationship between gut microbiota and neurodegenerative diseases: a genetic and epigenetic perspective.Metabolic brain disease · 2026Review
- Gut microbiota and brain aging: a comparative review of African and western populations.Frontiers in aging neuroscience · 2026Review
- Fucoidan Therapy for Extraintestinal Diseases: Targeting the Microbiota-Gut-Organ Axes.Biomolecules · 2025Review
- Faecal microbiota transplant in Parkinson's disease: pilot study to establish safety & tolerability.NPJ Parkinson's disease · 2025Article
- Inhibition of levodopa metabolism to dopamine by honokiol short-chain fatty acid derivatives may enhance therapeutic efficacy in Parkinson's disease.Scientific reports · 2025Article
- Exploring Gut Microbiota in Systemic Lupus Erythematosus: Insights and Biomarker Discovery Potential.Clinical reviews in allergy & immunology · 2025Review
- Article
- Supplementation of the Probiotic LLH135 Reduces Oxidative Stress in a Model of Hemiparkinsonism.Behavioural neurology · 2025Article
- Cold-pressed perilla seed oil: Investigating its protective influence on the gut-brain axis in mice with rotenone-induced Parkinson's disease.Food science & nutrition · 2024Article
- Gut microbial β-glucuronidases influence endobiotic homeostasis and are modulated by diverse therapeutics.Cell host & microbe · 2024Article
- The Crosstalk between Gut Microbiota and Nervous System: A Bidirectional Interaction between Microorganisms and Metabolome.International journal of molecular sciences · 2023Review
- Sodium butyrate ameliorates gut dysfunction and motor deficits in a mouse model of Parkinson's disease by regulating gut microbiota.Frontiers in aging neuroscience · 2023Article
- Gut-spine axis: a possible correlation between gut microbiota and spinal degenerative diseases.Frontiers in microbiology · 2023Review
- The Role of Microbiome in Brain Development and Neurodegenerative Diseases.Molecules (Basel, Switzerland) · 2022Review
- Neuroprotective Effect of Riboflavin Producing Lactic Acid Bacteria in Parkinsonian Models.Neurochemical research · 2022Article
- Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models.Molecular medicine reports · 2022Article
- Investigating neurological symptoms of infectious diseases like COVID-19 leading to a deeper understanding of neurodegenerative disorders such as Parkinson's disease.Frontiers in neurology · 2022Review
- The Emerging Scenario of the Gut-Brain Axis: The Therapeutic Actions of the New Actor Kefir against Neurodegenerative Diseases.Antioxidants (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by neuronal loss and dysfunction of dopaminergic neurons located in the substantia nigra, which contain a variety of misfolded α-synuclein (α-syn). Medications that increase or substitute for dopamine can be used for the treatment of PD. Recently, numerous studies have shown gut microbiota plays a crucial role in regulating and maintaining multiple aspects of host physiology including host metabolism and neurodevelopment. In this review article, the role of gut microbiota in the etiological mechanism of PD will be reviewed. Furthermore, we discussed current pharmaceutical medicine-based methods to prevent and treat PD, followed by describing specific strains that affect the host brain function through the gut-brain axis. We explained in detail how gut microbiota directly produces neurotransmitters or regulate the host biosynthesis of neurotransmitters. The neurotransmitters secreted by the intestinal lumen bacteria may induce epithelial cells to release molecules that, in turn, can regulate neural signaling in the enteric nervous system and subsequently control brain function and behavior through the brain-gut axis. Finally, we proved that the microbial regulation of the host neuronal system. Endogenous α-syn can be transmitted long distance and bidirectional between ENS and brain through the circulatory system which gives us a new option that the possibility of altering the community of gut microbiota in completely new medication option for treating PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.